【摘要】 目的 采用循證醫(yī)學的方法評價甘露聚糖肽聯(lián)合順鉑對比單用順鉑治療惡性胸腔積液的有效性和安全性。 方法 計算機檢索中國生物醫(yī)學文獻數(shù)據(jù)庫、中國期刊全文數(shù)據(jù)庫、中文科技期刊全文數(shù)據(jù)庫、萬方數(shù)據(jù)庫，收集甘露聚糖肽聯(lián)合順鉑對比單用順鉑治療惡性胸腔積液的隨機對照試驗，檢索時間為各數(shù)據(jù)庫建庫至2011年3月。對文獻進行質(zhì)量評價，用RevMan 5.0軟件對數(shù)據(jù)進行Meta分析。 結(jié)果 共納入6項研究，所有文獻質(zhì)量均為C級。共收入388例患者，Meta分析結(jié)果顯示甘露聚糖肽聯(lián)合順鉑組與單用順鉑組相比，總有效率前者高于后者，差異有統(tǒng)計學意義（Plt;0.05）；消化道不良反應發(fā)生率兩組組間差異無統(tǒng)計學意義（P=0.05）；骨髓抑制發(fā)生率前者低于后者，差異有統(tǒng)計學意義（Plt;0.05）；Karnofsky評分提高率前者高于后者，差異有統(tǒng)計學意義（Plt;0.05）?！〗Y(jié)論 系統(tǒng)評價表明，甘露聚糖肽聯(lián)合順鉑治療惡性胸腔積液的療效優(yōu)于單用順鉑的方案?！続bstract】 Objective To assess the clinical efficacy and safety of mannatide plus cisplatin treating malignant pleural effusion. Methods Literatures were retrieved from CBM, VIP, CNKI, Wanfang databases by computer. Literatures were enrolled according to inclusion and exclusion criteria, and the quality of studies was evaluated according to the Cochrane Library handbook. The period duration of searching was between the establishment of the databases and March, 2011. Meta-analysis was conducted by RevMan 5.0 software. Results The meta-analysis of 6 included RCT, all ranked C, which involved 388 patients. The Meta-analysis showed that the total effective rate in mannatide plus cisplatin group significantly differed from that in cisplatin group (P＜0.05). There were no significant difference in the adverse reaction of digestive tract between the two intervention groups (P=0.05). The adverse reaction of marrow depression inmannatide plus cisplatin group was much lower than that in cisplatin group (P＜0.05). The increase of KPS in mannatide plus cisplatin group was higher than that in cisplatin group (P＜0.05). Conclusions The analysis indicates mannatide plus cisplatin has a better effect on malignant pleural effusion than single cisplatin. However, the reliability of this review is affected by poor quality of included studies, and large-scale randomized controlled trials of high quality are needed to confirm the conclusions above.